EyeGene Inc

EyeGene Inc maintains a strong liquidity position with a current ratio of 8.53, indicating the company can easily cover its short-term liabilities with its current assets. The company holds KRW 5,966,751,760 in cash and equivalents, which is significantly higher than its total liabilities of KRW 13,238,525,140. However, the company's liquidity is not supported by positive operating cash flow, as it reported negative operating cash flow of KRW -6,005,316,420 in the latest period.

The company's profitability metrics are weak, with a return on equity (ROE) of -5.25% and a return on assets (ROA) of -4.28%. These figures indicate that EyeGene Inc is not generating returns for its shareholders or effectively utilizing its assets. The company reported a net loss of KRW -3,069,457,260 and an operating loss of KRW -3,573,258,180 in the latest financial period. These results are below the industry median for profitability metrics, suggesting underperformance relative to its peers.

EyeGene Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic breakdown provided in the available data. The lack of geographic diversification may expose the company to regional economic or regulatory risks, though the exact nature of these risks is not quantified in the available data.

The company's growth trajectory is uncertain, with no clear indication of revenue growth in the latest period. The reported revenue of KRW 523,309,530 is lower than the analyst estimate of KRW 3,363,420,000, suggesting a significant underperformance. The outlook for the current and next fiscal years is not provided in the available data, making it difficult to assess future growth potential.

Risk factors for EyeGene Inc include its negative net income and operating income, which raise concerns about its long-term viability. The company's liquidity risk is low due to its strong cash position, but its credit risk is elevated due to the lack of profitability and negative cash flows. The risk of dilution is currently low, as there are no immediate filing-based flags indicating potential share issuance. However, the company's negative free cash flow of KRW -2,907,020,070 may necessitate future financing, which could lead to dilution.

Recent events for EyeGene Inc include the release of its latest financial results, which show a significant decline in revenue and profitability compared to analyst expectations. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational performance.

Operating income improved by 51.2% year-over-year, signaling a meaningful reduction in operational losses for the company.

Net income losses narrowed by 42.5% year-over-year, indicating a positive trend toward improved profitability metrics.

The debt-to-equity ratio of 0.05 ranks above the median, suggesting a conservative capital structure with low leverage risk.

Cash conversion of 1.96 exceeds the 75th percentile of the pharmaceutical cohort, highlighting superior cash flow efficiency.

Dilution, liquidity, and credit risks are all assessed as low, providing a stable risk profile for investors.

The company reported a net loss of 12.1 billion KRW in the latest fiscal year, demonstrating an inability to generate profit.

Free cash flow remained deeply negative at -15.5 billion KRW, indicating significant ongoing cash burn and funding needs.

Operating margin of -6.8% places the company in the bottom quartile of the pharmaceutical cohort, reflecting poor operational efficiency.

Return on equity of -5.25% ranks in the bottom quartile, showing the company destroys shareholder value relative to peers.

Revenue growth CAGR of only 0.9% over four years suggests stagnant top-line expansion and limited market traction.

Revenue KRW 774.0M, −41,0% YoY; Operating income −37,2% YoY.

• ▍Revenue KRW 774.0M, −41,0% YoY
• ▍Operating income −37,2% YoY
• ▍Net income −216,1% YoY
• ▍Free cash flow −410,1% YoY
• ▍Net margin -1141.4%

Revenue KRW 1.10B, +14,4% YoY; Operating income +54,3% YoY.

• ▍Revenue KRW 1.10B, +14,4% YoY
• ▍Operating income +54,3% YoY
• ▍Net income +54,1% YoY
• ▍Free cash flow +55,0% YoY
• ▍Net margin -138.1%

Revenue KRW 877.3M, +56,3% YoY; Operating income +33,9% YoY.

• ▍Revenue KRW 877.3M, +56,3% YoY
• ▍Operating income +33,9% YoY
• ▍Net income +18,4% YoY
• ▍Free cash flow +65,6% YoY
• ▍Net margin -275.6%

Revenue KRW 3.57B, +6,3% YoY; Operating income +9,8% YoY.

• ▍Revenue KRW 3.57B, +6,3% YoY
• ▍Operating income +9,8% YoY
• ▍Net income −29,5% YoY
• ▍Free cash flow −17,3% YoY
• ▍Net margin -440.3%

Revenue KRW 5.29B, +63,3% YoY; Operating income +35,9% YoY.

• ▍Revenue KRW 5.29B, +63,3% YoY
• ▍Operating income +35,9% YoY
• ▍Net income +24,9% YoY
• ▍Free cash flow +28,1% YoY
• ▍Net margin -490.3%

Revenue KRW 3.24B; Operating income -KRW 36.86B.

• ▍Revenue KRW 3.24B
• ▍Operating income -KRW 36.86B
• ▍Net margin -1066.2%